Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

Cancer
Karyopharm said the FDA told it during a meeting that topline trial results would not likely be sufficient for Xpovio's approval in endometrial cancer • Source: Shutterstock

More from Anticancer

More from Therapeutic Category